Serum pyridinolines as specific markers of bone resorption in hemodialyzed patients

Niwa, Toshimitsu; Shiobara, Kazutaka; Hamada, Tomofumi; Miyazaki, Takashi; Tsukushi, Saori; Uema, Kanji; Tsuzuki, Takeshi

doi:10.1016/0009-8981(95)06012-8

Cited by 24 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intra-and inter-assay CVs for serum h-CTx were 2.6% and 4.1%, respectively (Furumitsu et al, 2000). Serum PYD and DPD were determined by high-performance liquid chromatography (HPLC) as previously described (Niwa et al, 1995); the intra-and inter-assay CVs were 1.3% and 3.4%, respectively for serum PYD, and 6.8 and 6.2%, respectively for DPD (Okabe et al, 2001).…”

Section: Serum Bone Resorption Markersmentioning

confidence: 99%

Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH

Ueda¹,

Inaba²,

Okuno³

et al. 2005

Life Sciences

View full text Add to dashboard Cite

Section: Serum Bone Resorption Markersmentioning

confidence: 99%

Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH

Ueda¹,

Inaba²,

Okuno³

et al. 2005

Life Sciences

View full text Add to dashboard Cite

“…Serum ␤-CTX was determined by an Elecsys ␤-CrossLaps TM serum assay (Roche Diagnostics) (9 ) with an intraassay CV of 2.6% (9 ). Serum PYD and DPD were measured by HPLC (20 ) with intraassay CVs of 1.3% for serum PYD and 6.8% for serum DPD (21 ). Serum BAP and intact OC were measured with an enzyme immunoassay (ALK-PHASE-B; Metra Biosystems) (22 ) and with a 2-site IRMA (Mitsubishi Kagaku Bioclinical Laboratories), respectively.…”

Section: Biochemical Markers For Calcium and Bone Metabolismmentioning

confidence: 99%

Serum Concentrations of Cross-Linked N-Telopeptides of Type I Collagen: New Marker for Bone Resorption in Hemodialysis Patients

et al. 2005

View full text Add to dashboard Cite

Background: Urinary cross-linked N-telopeptide of type I collagen (NTX) is a reliable bone resorption marker in patients with metabolic bone disease. We assessed a clinically available serum NTX assay suitable for anuric patients on hemodialysis (HD). Methods: Serum concentrations of NTX, C-terminal telopeptide of type I collagen (␤-CTX), pyridinoline (PYD), and deoxypyridinoline (DPD) were determined as bone resorption markers, and those of bone alkaline phosphatase (BAP) and intact osteocalcin (OC) as bone formation markers, in 113 male HD patients (mean age, 59.3 years; mean HD duration, 67.7 months). Each patient's bone mineral density (BMD) in the distal third of the radius was measured twice, with a 2-year interval between measurements, by dual-energy x-ray absorptiometry. Results: Serum NTX correlated significantly with ␤-CTX, PYD, DPD, BAP, and intact OC. NTX, as well as ␤-CTX, PYD, DPD, BAP, and intact OC, correlated significantly with BMD at the time of measurement. NTX, ␤-CTX, and DPD correlated significantly with the annual change in BMD during the 2-year period thereafter, in contrast to PYD, BAP, and intact OC. Patients in the highest quartile of serum NTX concentrations showed the fastest rate of bone loss. The sensitivity and specificity for detecting rapid bone loss were 48% and 83%, respectively, for serum NTX.

show abstract

“…A selective determination of those 'cross-links' not peptide-bound can be performed by omitting the hydrolysis step (94)(95)(96). A selective determination of those 'cross-links' not peptide-bound can be performed by omitting the hydrolysis step (94)(95)(96).…”

Section: Technical Criteriamentioning

confidence: 99%

“…Presently only preliminary results are available concerning the determination of 'cross-link' compounds in serum and synovial fluid samples (95,96).…”

Section: Technical Criteriamentioning

confidence: 99%

Review

1996

CCLM

View full text Add to dashboard Cite

A review is given summarizing the present knowledge of bone turnover markers with special emphasis on biological, preanalytical and technical criteria in the proper judgement of efficacy and limitations of the methods employed. The marker substances may be either measures of bone formation or bone resorption.Markers of bone formation are bone alkaline phosphatase, osteocalcin and the carboxyl-terminal propeptide of procollagen type I. Bone alkaline phosphatase has proved to be superior to total alkaline phosphatase activity with respect to diagnostic sensitivity and specificity. Immunochemical techniques for measuring bone alkaline phosphatase show a cross-reactivity of 14-20% with liver alkaline phosphatase. However, this does not compromise the clinical usefulness of these assays except for patients with severe liver diseases. Osteocalcin is strictly bone-specific but shows numerous disadvantages with respect to apparent instability and discordant results as obtained by different methods; however, in certain diagnostic situations (corticosteroid-induced osteopenia, absence of destroyed bone architecture) osteocalcin may serve as a sensitive bone turnover marker. The carboxyl-terminal propeptide of procollagen type I generally shows low discriminating power in the diagnosis of bone diseases.The urinary excretion of pyridinium 'cross-links' has been carefully evaluated so far with respect to analytical performance and clinical usefulness. This marker may be a substitute for 4-hydroxyproline measurements as the method of choice for assessment of bone resorption. There are other degradation products from the telopeptide regions of bone-derived collagen type I which are excreted into the urine (N-telopeptides, CrossLaps™)\ these analytes are promising tools in the assessment of bone resorption but require further evaluation, in particular with respect to their extraskeletal clearance and putative origin outside bone. Moreover, their clinical usefulness may vary depending on the patient group examined. In contrast, the serum concentration of the cross-linked telopeptide region of collagen type I seems to lack both diagnostic specificity and sensitivity in the majority of patient groups. Tartrate-resistant acid phosphatase (as determined by the presently available methods) cannot be recommended as a routine tool for assessment of bone resorption.Brought to you by | University of Arizona Authenticated Download Date | 7/8/15 5:47 AM

show abstract

Serum pyridinolines as specific markers of bone resorption in hemodialyzed patients

Cited by 24 publications

References 15 publications

Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH

Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH

Serum Concentrations of Cross-Linked N-Telopeptides of Type I Collagen: New Marker for Bone Resorption in Hemodialysis Patients

Review

Contact Info

Product

Resources

About